These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 26413995)

  • 21. High MET receptor expression but not gene amplification in ALK 2p23 rearrangement positive non-small-cell lung cancer.
    Feng Y; Minca EC; Lanigan C; Liu A; Zhang W; Yin L; Pennell NA; Farver C; Tubbs R; Ma PC
    J Thorac Oncol; 2014 May; 9(5):646-53. PubMed ID: 24722154
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New metastatic model of human small-cell lung cancer by orthotopic transplantation in mice.
    Sakamoto S; Inoue H; Ohba S; Kohda Y; Usami I; Masuda T; Kawada M; Nomoto A
    Cancer Sci; 2015 Apr; 106(4):367-74. PubMed ID: 25640943
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cigarette smoking induces overexpression of hepatocyte growth factor in type II pneumocytes and lung cancer cells.
    Chen JT; Lin TS; Chow KC; Huang HH; Chiou SH; Chiang SF; Chen HC; Chuang TL; Lin TY; Chen CY
    Am J Respir Cell Mol Biol; 2006 Mar; 34(3):264-73. PubMed ID: 16254251
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biomarkers of response to gefitinib in non-small-cell lung cancer.
    Carbone DP
    Nat Clin Pract Oncol; 2004 Dec; 1(2):66-7. PubMed ID: 16264818
    [No Abstract]   [Full Text] [Related]  

  • 25. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.
    Rodig SJ; Shapiro GI
    Curr Opin Investig Drugs; 2010 Dec; 11(12):1477-90. PubMed ID: 21154129
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Crizotinib in the management of advanced-stage non-small-cell lung cancer.
    Loong HH; Mok K; Leung LK; Mok TS
    Future Oncol; 2015; 11(5):735-45. PubMed ID: 25757678
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Marsdenia tenacissima extract restored gefitinib sensitivity in resistant non-small cell lung cancer cells.
    Han SY; Zhao MB; Zhuang GB; Li PP
    Lung Cancer; 2012 Jan; 75(1):30-7. PubMed ID: 21757251
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular targeted agents and biologic therapies for non-small cell lung cancer.
    Somaiah N; Simon GR
    J Thorac Oncol; 2010 Dec; 5(12 Suppl 6):S434-54. PubMed ID: 21102235
    [No Abstract]   [Full Text] [Related]  

  • 29. Targeted therapies for non-small cell lung cancer.
    Dempke WC; Suto T; Reck M
    Lung Cancer; 2010 Mar; 67(3):257-74. PubMed ID: 19914732
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metastatic non-small cell lung cancer management: novel targets and recent clinical advances.
    Riess JW; Wakelee HA
    Clin Adv Hematol Oncol; 2012 Apr; 10(4):226-34. PubMed ID: 22706483
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeted therapy in nonsmall cell lung cancer.
    Puri T
    Indian J Cancer; 2017; 54(1):83-88. PubMed ID: 29199670
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MET signaling: novel targeted inhibition and its clinical development in lung cancer.
    Feng Y; Thiagarajan PS; Ma PC
    J Thorac Oncol; 2012 Feb; 7(2):459-67. PubMed ID: 22237263
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting the phosphatidylinosital 3-kinase, Akt, and mammalian target of rapamycin pathway in non-small cell lung cancer.
    Cuffe S; Leighl NB
    J Thorac Oncol; 2011 Nov; 6(11 Suppl 4):S1805-7. PubMed ID: 22005538
    [No Abstract]   [Full Text] [Related]  

  • 34. Inhibition of MET receptor tyrosine kinase and its ligand hepatocyte growth factor.
    Sadiq AA; Salgia R
    J Thorac Oncol; 2012 Dec; 7(16 Suppl 5):S372-4. PubMed ID: 23160322
    [No Abstract]   [Full Text] [Related]  

  • 35. A tabulated summary of targeted and biologic therapies for non-small-cell lung cancer.
    Somaiah N; Simon NG; Simon GR
    J Thorac Oncol; 2012 Dec; 7(16 Suppl 5):S342-68. PubMed ID: 23160320
    [No Abstract]   [Full Text] [Related]  

  • 36. Integrating new targeted agents into the treatment of non-small-cell lung cancer.
    Thatcher N
    Lung Cancer; 2006 Dec; 54 Suppl 2():S25-31. PubMed ID: 17056150
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Constitutive activation of met kinase in non-small-cell lung carcinomas correlates with anchorage-independent cell survival.
    Qiao H; Hung W; Tremblay E; Wojcik J; Gui J; Ho J; Klassen J; Campling B; Elliott B
    J Cell Biochem; 2002; 86(4):665-77. PubMed ID: 12210733
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The clinical significance of hepatocyte growth factor for non-small cell lung cancer.
    Siegfried JM; Weissfeld LA; Luketich JD; Weyant RJ; Gubish CT; Landreneau RJ
    Ann Thorac Surg; 1998 Dec; 66(6):1915-8. PubMed ID: 9930468
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Research Progress in Hepatocyte Growth Factor/Mesenchymal-epithelial Transition Factor Signaling Pathway:Effects and Mechanisms on Resistance to Targeted Therapy for Non-small Cell Lung Cancer].
    Chen HY; He Y
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2021 Apr; 43(2):259-264. PubMed ID: 33966707
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The update of emerging targeted therapies of lung cancer].
    Shang CC; Zhang L
    Zhonghua Nei Ke Za Zhi; 2017 Jun; 56(6):447-449. PubMed ID: 28592047
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.